Should investors consider a speculative bet in Ebola treatments? In an article titled “The Free Market Won’t Produce an Ebola Cure,” Forbes contributor Tim Worstall argues the market for Ebola cures is significantly low, and thus a free market cure to the medical crisis grounded in poor West African nations isn’t likely to gain traction. But what if the disease spreads into more wealthy nations? What if the deadly virus suddenly gets legs throughout the world? Tekmira Pharmaceuticals benefiting from Ebola crisis Benefiting from such a terrible situation would be Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), which recently received news the US…
Tekmira Pharmaceuticals Corporation (TKMR) Stock Benefits From Ebola Crisis
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.